

Anesthesiology  
67:581-583, 1987

## A Report of Hepatic Necrosis and Death Following Isoflurane Anesthesia

THOMAS W. CARRIGAN, M.D.,\* WILLIAM J. STRAUGHEN, M.D.†

Several halogenated anesthetics have been associated with hepatotoxicity. Yet, isoflurane has not been reported to cause liver damage in humans. The following is a report of a patient who had hepatic failure and death after receiving an anesthetic that included isoflurane.

### CASE REPORT

On March 7, 1986, a 44-yr-old white woman was admitted for lysis of abdominal adhesions. She had no medical problems except chronic hypogastric pain presumed to be secondary to adhesions from previous surgeries. Her surgical history included four abdominal procedures, each with exposure to halogenated anesthetics: 3/74 hysterectomy—halothane, 4/84 cholecystectomy—enflurane, 5/85 hernia repair—enflurane, and 11/85 lysis of adhesions—isoﬂurane. She denied a history of hepatitis or blood transfusions. She had no allergies, but reported nausea after taking oral codeine. Prior to admission, she had a minor dental procedure, and was taking oral phenoxymethyl penicillin. There was no history of smoking or alcoholic intake.

The admission physical examination revealed a healthy-appearing female, of medium build, with normal vital signs. She was not icteric, and showed no skin manifestation of liver disease. No adenopathy was noted. Cardiopulmonary findings were normal. The abdomen was not distended. There were several well-healed laparotomy scars. The liver and spleen were not palpable. The extremities were well-developed and without edema. The preoperative aspartate aminotransferase, alanine aminotransferase, bilirubin, alkaline phosphatase, and coagulation profile were normal. The white blood cell count was slightly elevated at 14,500/mm<sup>3</sup>, with no immature forms.

She was taken to surgery the following morning. Preoperatively, the patient received midazolam 4 mg iv. Anesthesia was induced with sufentanil 25 µg and metocurine 2 mg, followed by thiopental 250 mg and succinylcholine 100 mg. Anesthesia was maintained with a mixture of 50% oxygen and nitrogen with isoflurane 0.5–0.8%. Twenty-five micrograms of sufentanil were added. Atacurium 20 mg was administered for relaxation. Intraoperative monitoring included electrocardiogram, esophageal stethoscope and temperature probe, nerve stimulator, and oxygen analyzer. Continuous mechanical ventilation was used without PEEP. The Dräger-Narkomed 2A machine was used.

The laparotomy was performed and multiple dense adhesions were

observed between the liver, stomach, small intestine, and anterior abdominal wall. These were removed by sharp dissection. No retractors or packs were used in the area of the hepatic artery or portal vein. A solution of Solu-Cortef 100 mg, Hyskon 100 ml, and 100 ml saline was instilled into the abdominal cavity. Forty milliliters bupivacaine 0.25% was injected into the abdominal fascia. There was no period of intraoperative hypotension. Total blood loss was 200 milliliters. Fluid replacement was made with 600 milliliters dextrose 5% Ringer's Lactate. Anesthesia was reversed using edrophonium 40 mg, atropine 0.4 mg, and naloxone 0.1 mg. The duration of anesthesia was 90 min.

The patient tolerated the surgery and anesthesia well, and was taken to the recovery room and extubated while awake. She remained on electrocardiographic monitoring, and her vital signs were taken every 15 min. The patient did well, and was transferred back to her room that same afternoon. That evening she complained of nausea, but was otherwise asymptomatic.

The following morning she became lethargic, progressed to total unresponsiveness, and required mechanical ventilation. Her temperature was 99°. Serum bilirubin was 9.6 mg/dl, aspartate aminotransferase greater than 2,000 units/l, lactate dehydrogenase greater than 4,000 units/l, and prothrombin time greater than 180 s (control less than 12 s). Her serum ammonia level was 182 mmol/l (nl 11–35). Blood cultures showed no growth. The patient subsequently developed disseminated intravascular coagulation with fibrin split products at 1:160 dilution, fibrinogen 51 mg/dl, and platelets 70,000/mm. She continued to deteriorate, and expired on the fourth postoperative day.

A post-mortem examination was performed. The gross findings of the liver were consistent with acute fulminant necrosis. On light microscopy, there was evidence of canalicular cholestasis, which is often seen with drug reactions. No viral particles were demonstrated. Electron microscopy revealed no spherical or tubular structures or filaments in the nucleus or cytoplasm as seen with hepatitis B.

Serum for viral studies revealed negative assays for Hepatitis B surface antigen and B core antibody. Hepatitis A antibody was present; however, an IgM fraction was not detected, suggesting prior exposure to hepatitis A without current infection. Herpes virus I and II index (by ELISA) was negative. Cytomegalovirus (CMV) IgG (ELISA) was weakly positive. In light of the historical and clinical presentation, it is unlikely that the patient had active CMV hepatitis.

### DISCUSSION

Halogenated anesthetics have been associated with hepatic dysfunction. Halothane hepatotoxicity has been the most commonly studied,<sup>1–4</sup> and is the subject of a review by Stock and Strunin.<sup>5</sup> Halothane can produce a syndrome of clinical features<sup>4</sup> and laboratory findings<sup>6,7</sup> that are similar to viral hepatitis or drug-induced liver damage.<sup>4,8,9</sup> Following halothane exposure, susceptible patients may develop fever, mental changes, and elevated transaminase and bilirubin levels, as well as coagulation abnormalities. The histopathology spectrum is wide, ranging from panlobular to multifocal necrosis to fulminant necrosis.<sup>10</sup>

\* Chief Resident, Internal Medicine, Wright State University School of Medicine.

† Assistant Director, Pathology Department, Miami Valley Hospital.

Received from the Department of Internal Medicine, Wright State University School of Medicine, Dayton, Ohio; and the Department of Pathology, Miami Valley Hospital, Dayton, Ohio. Accepted for publication April 20, 1987.

Address reprint requests to Dr. Carrigan: Good Samaritan Hospital, Wright State University, Medical Education Department, 2222 Philadelphia Drive, Dayton, Ohio 45406.

Key words: Anesthetics, volatile: isoflurane. Liver: toxicity.

The mechanism of hepatic injury is unknown. Studies have been directed toward hypersensitivity reactions,<sup>11</sup> toxicity of intermediary metabolites,<sup>12</sup> multiplicity and duration of exposure,<sup>9,13</sup> hypoxia,<sup>14</sup> obesity,<sup>15,16</sup> and nutritional status<sup>17</sup> as factors potentially involved in halothane hepatotoxicity.

There is evidence to suggest cross reactivity between halothane and other halogenated anesthetics.<sup>18</sup> Other anesthetics, methoxyflurane,<sup>18,19</sup> and enflurane<sup>20</sup> have been associated with hepatic injury. Isoflurane, an isomer of enflurane, has not been shown to be hepatotoxic in humans, but can produce centrilobular necrosis in experimental animals.<sup>21</sup> In a study of 12 surgical patients, slight but insignificant ( $P < .05$ ) elevations in transaminases were noted following isoflurane anesthesia.<sup>22</sup> Fisher *et al.*<sup>23</sup> reported hepatic necrosis after isoflurane exposure, but concluded the cause to be herpes virus hepatitis.

McLaughlin and Eger<sup>24</sup> discussed a case of hepatic dysfunction following repeated exposure to isoflurane anesthesia, but dismissed isoflurane as the cause. Recently, Grégoire and Smiley<sup>25</sup> reported "the first case" of hepatitis attributable to isoflurane anesthesia. Their results do not show definitive causal relationship between isoflurane and liver dysfunction, and have received criticism from others.<sup>26</sup>

The cause of massive liver necrosis in this patient, which resulted in her death, is not clear. However, there is a temporal relationship of liver failure and exposure to isoflurane. It is of interest to us that features of this patient's history and clinical course have been observed in cases of anesthetic-associated hepatotoxicity. While liver damage after halogenated anesthesia is rare, and this rarity makes prospective randomized studies impractical, it may be useful to analyze case studies as reported here.

This patient had no history of preexisting liver disease, but she had been exposed to halogenated anesthetics several times—a feature thought by some to increase the likelihood of hepatotoxicity on reexposure.

She had been taking oral phenoxymethyl penicillin prior to hospitalization. Liver dysfunction has been reported in association with penicillin therapy. Asymptomatic reversible trans-aminasemia has been noted after parenteral ampicillin<sup>27,28</sup> and carbenicillin.<sup>28-30</sup> Liver tenderness, nausea and vomiting, and transaminase elevations have followed administration of parenteral oxacillin.<sup>31,32</sup> Liver necrosis associated with anaphylactic shock has been reported after intramuscular penicillin.<sup>33</sup> This patient had taken oral penicillin several days prior to her preoperative chemistry profile. The liver enzymes were all within normal limits at that time.

Preoperatively, the patient received thiopental and narcotics. Albeit rare, these drugs have been associated with liver dysfunction.<sup>34,35</sup>

Disturbances in hepatic blood flow can account for liver necrosis in surgical patients. There were no retractors or packs used in the area of hepatic artery or portal vein during this operation. However, hepatic blood flow is diminished during many surgical procedures; the decrease is directly related to the degree of surgical trauma.<sup>36</sup> It is unlikely that a short, uncomplicated laparotomy with lysis of abdominal adhesions, and no periods of intraoperative hypotension, could account for the massive necrosis observed in this woman.

Hyskon (Dextran 70) was instilled into the abdomen for prevention of adhesions. Anaphalactoid reactions have been reported with intravenous glucose polymers,<sup>37,38</sup> but his patient did not receive intravenous Dextran 70. One might speculate that the Dextran 70 was absorbed from the peritoneum, precipitated vascular spasm of the hepatic artery, and caused hepatic ischemia and subsequent injury. This would probably be accompanied also by spasm of the mesenteric arteries, and ischemic necrosis of the large and small intestines. Necropsy findings of the intestines, pancreas, and spleen do not support occlusive vascular events in the branches of the celiac or mesenteric arteries. However, the liver is at a disadvantage when considering ischemia, because the majority of blood perfusing the liver is from the portal circulation, and is highly deoxygenated.

Common features said to be related to halogenated anesthetic hepatitis have been reported.<sup>4,11</sup> Eger and Smuckler,<sup>39</sup> in a study of enflurane, devised a "syndrome score," and examined 12 variables. Although our patient did not receive enflurane, she demonstrated eight positive features: 1) prior anesthesia with halogenated anesthetics; 2) nausea; 3) anorexia; 4) jaundice; 5) total bilirubin exceeding 2.5 mg/dl; 6) serum glutamic-oxaloacetic transaminase (now referred to as aspartate aminotransferase or AST) above 370 IU; 7) hepatic necrosis; and 8) death of the patient. Features of "the syndrome score" not demonstrated in this patient were: 1) fever; 2) chills; 3) rash; and 4) eosinophilia. In addition, the patient was not obese and did not have a history of atopy.

We have evidence to exclude viral hepatitis due to hepatitis A, hepatitis B, Herpes I or II, Epstein-Barr, or cytomegalovirus. It is possible this patient had subclinical non-A, non-B hepatitis, but unlikely, as she had no history of blood transfusions or known contact with carriers.

In summary, we cannot conclude that isoflurane was the cause of the fulminant hepatic failure which resulted in the death of this patient. However, many (but

not all) factors thought to be associated with anesthetic-induced hepatitis were present. Further, we attempted to exclude other possibilities which could account for the rapid development of hepatic necrosis. If isoflurane does cause hepatic injury in rare patients, reports such as this one will be needed to aid in the identification of patients at risk.

REFERENCES

1. Lindenbaum J, Leifer E: Hepatic necrosis associated with halothane anesthesia. *N Engl J Med* 268:525-530, 1963
2. Trey C, Lipworth L, Chalmers TC, Davidson C, Gottlieb S, Popper H, Sanders S: Fulminant hepatic failure presumable contribution of halothane. *N Engl J Med* 279:798-801, 1968
3. Klion FM, Schaffner F, Popper H: Hepatitis after exposure to halothane. *Ann Intern Med* 71:467-477, 1969
4. Subcommittee on the National Halothane Study: Summary of the National Halothane Study. *JAMA* 197:775, 1966
5. Stock GL, Strunin L: Unexplained hepatitis following halothane anesthesia. *ANESTHESIOLOGY* 63:424-439, 1985
6. Babior BM, Davidson CS: Postoperative massive liver necrosis, clinical and pathological study. *N Engl J Med* 276:645-652, 1967
7. Corbett TH: Pharmacology and toxicology of halogenated anesthetics. *Adv Pharmacol Chemother* 16:196-212, 1973
8. Gall EA: Report of the pathology panel. National Halothane Study. *ANESTHESIOLOGY* 29:233-248, 1968
9. Carney FTM, Vandyke RA: Halothane hepatitis: A critical review. *Anesth Analg* 51:135-142, 1972
10. Benjamin SB, Goodman ZD, Kamal IG, Zimmerman HJ, Irey NS: The morphologic spectrum of halothane-induced hepatic injury: Analysis of 77 cases. *Hepatology* 5:1163-1171, 1985
11. Brown BR Jr, Geha DC: Inhalational anesthetics and hepatic injury, Complications in Anesthesiology. Edited by Orkin FK, Cooperman LH. Philadelphia, JB Lippincott Co, 1983, p 436
12. Brown BR, Sipes IG: Biotransformation and hepatotoxicity of halothane. *Biochem Pharmacol* 26:2092-2094, 1977
13. Fee JPH, Black GW, Dundee JW, McIlroy PDA, Johnston HML, Johnston SB, Black IHC, McNeill HC, Neill DW, Daggart JR, Merrett JD, McDonald JR, Bradley DSG, Haire M, McMillan SA: A prospective study of liver enzyme and other changes following repeat administration of halothane and enflurane. *Br J Anaesth* 51:1133-1141, 1979
14. Nimmo WS: Drug reactions and the liver (editorial). *Br J Anaesth* 52:1059-1060, 1980
15. Dundee JW: Problems of multiple inhalation anesthetics. *Br J Anaesth* 53:635-675, 1981
16. Touloukian J, Kaplowitz N: Halothane-induced hepatic disease. *Semin Liver Dis* 1:134-142, 1981
17. Van Dyke RA: Metabolism of anesthetic agents: Toxic implications. *Acta Anaesthesiol Scand (Suppl)*75:7-9, 1975
18. Joshi PH, Conn HO: The syndrome of methoxyflurane associated hepatitis. *Ann Intern Med* 80:395-401, 1974
19. Brenner AI, Kaplan MM: Recurrent hepatitis due to methoxyflurane anesthesia. *N Engl J Med* 284:961-962, 1971
20. Lewis JH, Zimmerman HJ, Ishak KG, Mullick FG: Enflurane hepatotoxicity: A clinico-pathologic study of 24 cases. *Ann Intern Med* 98:984-992, 1983
21. Van Dyke RA: Hepatic centriobular necrosis in rats after exposure to halothane, enflurane or isoflurane. *Anesth Analg* 61:812-819, 1982
22. Luu K, Luciana S, Chao C: Minimal hepatic and renal function changes after isoflurane anesthesia. *Anesthesiologica Sinica* 23:100-103, 1985
23. Fisher NA, Iwata RT, Eger EI II, Smuckler EA: Hepatic necrosis associated with herpes virus after isoflurane anesthesia. *Anesth Analg* 64:1131-1133, 1985
24. McLaughlin DF, Eger EI II: Repeated isoflurane anesthesia in a patient with hepatic dysfunction. *Anesth Analg* 63:775-778, 1984
25. Grégoire S, Smiley RK: Acute hepatitis in a patient with mild factor IX deficiency after anesthesia with isoflurane. *Can Med Assoc J* 135:645-646, 1986
26. Webster JA: Acute hepatitis after isoflurane anesthesia (letter). *Can Med Assoc J* 135:1343-1344, 1986
27. Nelson JD, Haltain KC: Broad spectrum penicillins in enteric infections of children. *Ann NY Acad Sci* 145:414-422, 1967
28. Knirsch AK, Gralla EJ: Abnormal serum transaminase levels after parenteral ampicillin and carbenicillin administration. *N Engl J Med* 282:1081-1082, 1970
29. Boxerbaum B, Doershuk CF, Matthews LW: Use of carbenicillin in patients with cystic fibrosis. *J Infect Dis* 122(suppl):S59-S61, 1970
30. Bodey GP, Whitecar JR Jr, Middleman E, Rodriguez V: Carbenicillin therapy for pseudomonas infections. *JAMA* 218:62-66, 1971
31. Dismukes WE: Oxacillin-induced hepatic dysfunction. *JAMA* 1226:861-863, 1973
32. Ten Das A, Quinn EL: Cholestatic hepatitis following the administration of sodium oxacillin. *JAMA* 191:674-675, 1965
33. Murphy ES, Mireles V: Shock, liver necrosis, and death after penicillin injection. *Arch Pathol Lab Med* 73:13-20, 1962
34. Vaizey IM: Toxic jaundice following administration of pentothal. *Br J Anaesth* 15:55-59, 1938
35. Shingu K, Eger EI III, Johnson BH: Hepatic injury induced by anesthetic agents in rats. *Anesth Analg* 62:140-145, 1983
36. Gelman SI: Disturbances in hepatic blood flow during anesthesia and surgery. *Arch Surg* 111:881-883, 1976
37. Krenzlok EP, Parker WA: Dextran 40 anaphylaxis. *Anesth Analg* 54:736-738, 1975
38. Ring J, Messmer K: Incidence and severity of anaphylactoid reactions in colloid volum substitutes. *Lancet* 1:466-469, 1977
39. Eger EI II, Smuckler EA, Ferrell LD, Goldsmith CH, Johnson BH: Is enflurane hepatotoxic? *Anesth Analg* 65:21-30, 1986